ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
PipelineReview.com3d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...
College of Natural Sciences5d
Top Prize Image for Visualizing Science Shows a Logistic Map’s Chaotic Portion
The college’s Visualizing Science competition finalists include the winning image of a Logistic Map’s Chaotic Portion by an ...
Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial
NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...
I’ve been drinking kombucha for years and it’s transformed my gut health – here’s how
B efore 2025 was named the year of the health drink, before matcha lattes became a status symbol and before anyone was ...
Morning Update: How COVID shaped and shattered public health
It is, somehow, the fifth anniversary of the COVID pandemic – more on that below, along with new violence in Syria and Loblaw ...
clinicaltrialsarena3d
MSD to push for approval of HIV combo after Phase III success
Meanwhile, an open-label trial enrolled ... to prevent the HIV from multiplying. Meanwhile, Islatravir is a reverse transcriptase inhibitor that causes premature termination of DNA transcription ...
Researchers develop method to identify dormant cells that carry HIV
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...